Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Grifols, S.A.NASDAQ: GRFS

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows in line with its trailing trend

Q2 FY2026 depreciation & amortization of €107M rose 0.0% year over year, behind the +1.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.

Context

  • Depreciation & amortization amounted to 6.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +1.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€107M+1.2% QoQ
Last fiscal yearDec 2025
€432.24M-1.3% YoY
LTMJun 2026
€443.93M+1.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-1.3%——
3-year CAGR+1.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
432.24M EUR
Year-over-year change
-1.3%
4-year CAGR
+4.7%

Depreciation & Amortization vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.5% is the 2nd highest of 9, against a peer median of -3.7%.
  • Depreciation & amortization amounts to 6.0% of revenue for GRFS, versus a peer median of 8.0%.
GRFS Competitors
Depreciation & Amortization for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Jun 2026$3.33B USD+5.9%-1.6%7.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$2.24B USD-4.2%-0.7%11.1%
QDELQuidelOrtho CorporationLTM Mar 2026$447.8M USD+0.5%+15.9%16.9%
GRFSGrifols, S.A.LTM Jun 2026€443.93M EUR+1.5%+1.7%6.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M USD-23.5%+6.4%4.9%
HAEHaemonetics CorporationLTM Jun 2026$110.07M USD-4.5%+6.2%8.1%
TECHBio-Techne CorporationLTM Sep 2026$96.75M USD-8.8%-3.2%7.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M USD-3.2%+16.6%27.3%
ADMAADMA Biologics, Inc.LTM Jun 2026$7.69M USD-2.8%+4.4%1.5%
Peer median (excluding GRFS) —-3.7%+5.3%8.0%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income188.73M361.26M207.02M444M386.13M
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(181.36M)(609.22M)(362.84M)22.38M(24.01M)
Accounts Receivables(16.81M)(80.17M)(68.82M)(41.88M)(30.74M)
Inventory(157.47M)(600.25M)(411.44M)25.82M(93.17M)
Accounts Payables080.21M0090.29M
Other Working Capital(7.08M)(9.01M)117.41M38.44M9.61M
Other Non-Cash Items229.84M(173.89M)(71.91M)(2.1M)211.32M
Operating Cash Flow596.98M(10.87M)218.69M902.17M1.01B
Capital Expenditures(247.37M)(375.56M)(310.32M)(371.37M)(254.54M)
Acquisitions (Net)(519.13M)(1.44B)(29.47M)(285.87M)(99.9M)
Purchases of Investments0(164.66M)(93.31M)(43.85M)(54.75M)
Sales of Investments0015.14M04.8M
Other Investing Activities(87.65M)3.28M(62.64M)1.45B0
Investing Cash Flow(854.15M)(1.98B)(394.72M)886.67M(556.15M)
Debt Repayment2.75B(104.29M)(116.39M)(111.49M)(119M)
Common Stock Issued00000
Common Stock Repurchased(125.7M)(3.46M)00(123.91M)
Dividends Paid(252.44M)(592K)0(962K)(122.95M)
Other Financing Activities(70.56M)(65.16M)287.89M(1.25B)(142.26M)
Financing Cash Flow2.3B(173.49M)171.49M(1.36B)(508.12M)
Effect of Forex Changes55.46M35.55M(15.09M)20.08M19.75M
Net Change in Cash2.1B(2.13B)(19.63M)450.2M(38.85M)
Free Cash Flow349.6M(386.43M)(91.63M)530.8M751.14M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.